Clinical Trials on Essential Tremor

Total 8674 results

PharmaEssentia

Recruiting

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

Essential Thrombocythemia

United States, Canada
Yuhan Corporation

Completed

Anagre Cap. in Patients With High-Risk Essential Thrombocythemia

Essential Thrombocythemia

Korea, Republic of
AOP Orphan Pharmaceuticals AG

Completed

Anagrelide Retard in Essential Thrombocythemia (TEAM-ET)

Essential Thrombocythemia

Austria, Bulgaria, Lithuania, Poland, Russian Federation
Bristol-Myers Squibb

Recruiting

A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Real World Evidence of Fedratinib Effectiveness in MF (REALFed)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Italy
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Terminated

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Thailand, Malaysia, Korea, Republic of, Italy, United Kingdom, Poland, Germany, Turkey
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Completed

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Canada
Novartis Pharmaceuticals

Completed

A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis (JAKoMo)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Germany
Novartis Pharmaceuticals

Completed

Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosis

Idiopathic Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia-Vera Myelofibrosis

United Kingdom, Ireland, Germany, Italy, France
AstraZeneca
University of Texas; Gustave Roussy, Cancer Campus, Grand Paris; New York City...

Completed

Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

Primary Myelofibrosis (PMF) | Post-Polycythaemia Vera | Essential Thrombocythaemia Myelofibrosis

United States, France
Curtin University

Active, not recruiting

Long-term Use of CCB and Breast Cancer Risk

Breast Cancer | Hypertension,Essential

Australia
Yonsei University

Recruiting

Comparison of the Electric Plasma Surgical Tool "PlasmaBlade" for Replacement of the Deep Brain Stimulation (DBS) Devices With Conventional Surgery

Epilepsy | Parkinson Disease | Dystonia | Essential Tremor

Korea, Republic of
Oslo University Hospital
University of Oslo; Umeå University; University of Geneva, Switzerland

Active, not recruiting

Nutrition Therapy in the Immature Infant (ImNuT) (ImNuT)

Immature Infant | Essential Fatty Acid Deficiency

Norway
Mustafa Kemal University

Recruiting

Functional Inspiratory Muscle Training in Patients Diagnosed With Hypertension

Hypertension,Essential

Turkey
Incyte Corporation

Completed

Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States
Merck Sharp & Dohme LLC

Recruiting

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

Primary Myelofibrosis | Polycythemia Vera | Thrombocythemia, Essential | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Australia, New Zealand
M.D. Anderson Cancer Center

Recruiting

Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Myelofibrosis Transformation in Essential Thrombocythemia

United States
Incyte Corporation

Recruiting

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders (LIMBER)

Anemia | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, France, Italy, Japan, United Kingdom, Canada
CTI BioPharma
PSI CRO

Recruiting

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of, Spain, Canada, Czechia, United States, Australia, France, Hungary, United Kingdom, Romania, Belarus, Bulgaria, Georgia, Germany, Israel, Italy, Poland, Russian Federation, Serbia, Ukraine, Bosnia and Herzegovina and more
Incyte Corporation

Active, not recruiting

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Primary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Spain, United Kingdom, Korea, Republic of, China, Japan, France, Turkey, Germany, Israel, Poland, Belgium, Italy, Austria, Denmark, Finland, Norway
Constellation Pharmaceuticals

Active, not recruiting

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) (MANIFEST-2)

Primary Myelofibrosis | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of, Spain, United States, Canada, Taiwan, Czechia, United Kingdom, Australia, Italy, Belgium, Germany, France, Israel, Greece, Malaysia, Netherlands, Austria, Turkey, Poland, Thailand, Hong Kong, Hungary
University of Utah
Karyopharm Therapeutics Inc

Active, not recruiting

Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors (ESSENTIAL)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States
Samus Therapeutics, Inc.

Terminated

Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis

Primary Myelofibrosis | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (REALISE)

Primary Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis | Post-Polycythemia Vera-Myelofibrosis

Belgium, Italy, Spain, Bulgaria, Turkey, Greece, Russian Federation, Austria, Canada, Japan, Germany
John Mascarenhas
National Cancer Institute (NCI); Novartis; Incyte Corporation; Myeloproliferative...

Terminated

Ruxolitinib Prior to Transplant in Patients With Myelofibrosis

Primary Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Canada, United Kingdom
John Mascarenhas

Terminated

Anti-TGF-beta Therapy in Patients With Myelofibrosis

Primary Myelofibrosis | Myelofibrosis | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | Post-essential Thrombocythemia Related Myelofibrosis

United States
Merck Sharp & Dohme LLC

Not yet recruiting

Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)

Essential Thrombocythemia
Merck Sharp & Dohme LLC

Recruiting

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Essential Thrombocythemia

Poland, Israel, Australia, Hong Kong, Japan, New Zealand, Taiwan, Korea, Republic of, United States, Spain, Italy, Netherlands, Germany
The University of Texas Health Science Center at...
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...

Recruiting

Hematology, IMG-7289, LSD1 (Lysine-Specific Demethylase 1) Inhibitor, Essential Thrombocythemia (ET), Ph 2

Thrombocythemia, Essential

United States
Imago BioSciences, Inc., a subsidiary of Merck...

Completed

Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

Essential Thrombocythemia

United States, Australia, New Zealand, United Kingdom, Hong Kong, Germany, Italy
French Innovative Leukemia Organisation
Novartis Pharmaceuticals

Terminated

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

Essential Thrombocythemia

France
Shire

Completed

French Observational Xagrid (FOX) Study In Adult Patients With Essential Thrombocythemia (FOX)

Essential Thrombocythemia

France
Veloxis Pharmaceuticals

Completed

Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO) (STRATO)

Renal Failure | Tremors

United States
Addpharma Inc.

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of Co-administration of AD-227A and AD-227B

Essential Hypertension
Hanmi Pharmaceutical Company Limited

Recruiting

A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients With Essential Hypertension (HM_APOLLO)

Hypertension

Korea, Republic of
Ceric Sàrl
Electroducer

Not yet recruiting

Feasibility Study Evaluating the Safety and Efficacy of the Renal Stimulation by Direct Wire Pacing, During Renal Denervation Procedure (RNS by DWP)

Essential Hypertension
Cairo University
STDF

Recruiting

Effect of DNS Exercises Training on Hypertension

Essential Hypertension

Egypt
Ahn-Gook Pharmaceuticals Co.,Ltd
Daehwa Pharmaceutical Co., Ltd.

Not yet recruiting

Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS

Essential Hypertension
Celltrion

Active, not recruiting

Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects

Essential Hypertension

Korea, Republic of
Organon and Co

Completed

BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333) (EASE)

Hypertension
Celltrion Pharm, Inc.

Completed

A Study for PMS of AZL-M/CLD FDC in the Treatment of Participants With Essential HTN in South Korea

Essential Hypertension

Korea, Republic of
University of Copenhagen
University of Aarhus

Completed

Repurposing Colchicine to Improve Vascular Function in Hypertension (RECTIFHY)

Essential Hypertension

Denmark
Idorsia Pharmaceuticals Ltd.

Completed

Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension

Essential Hypertension

United States, Canada, Israel, Puerto Rico
Dokuz Eylul University

Completed

The Effect of the Use of BATHE Interview Technique on Treatment Compliance in Hypertension Patients in Primary Care

Essential Hypertension

Turkey
Organon and Co

Terminated

An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325)

Hypertension
Organon and Co

Completed

Antihypertensive Efficacy and Safety of Approved Drugs in Japanese Patients With Essential Hypertension (Banyu Study)(0954A-302)

Hypertension
Silkiss Eye Surgery
Jazz Pharmaceuticals; Smith-Kettlewell Eye Research Institute; Benign Essential...

Completed

Effect of Non-psychoactive Cannabidiol as an Adjunct to Botulinum Toxin in Blepharospasm

CBD | Blepharospasm | Blepharospasm, Benign Essential

United States
Boryung Pharmaceutical Co., Ltd

Completed

BR1010 in Patients With Essential Hypertension Patients Who do Not Adequately Respond to Fimasartan/Amlodipine Combination (FINAL)

Essential Hypertension

Korea, Republic of
Chinese University of Hong Kong

Completed

BRAVE Study With Uncontrolled Essential Hypertension (BRAVE Study) (BRAVE)

Hypertension

Hong Kong
Ahn-Gook Pharmaceuticals Co.,Ltd

Unknown

Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension

Hypertension

Clinical Trials on Essential Tremor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Peru

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations